Suggested remit: To appraise the clinical and cost effectiveness of itulazax 12 standardised quality pollen from white birch (betula verrucosa) sublingual lyophilisate immunotherapy (12 SQ-Bet SLIT) within its marketing authorisation for treating moderate-to-severe allergic rhinitis, conjunctivitis, or both, induced by pollen from the birch homologous group in people 5 to 17 years old.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6537
Provisional Schedule
- Committee meeting: 1:
- 17 June 2026
- Expected publication:
- 26 August 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- ALK-Abello
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Allergy UK
- Anaphylaxis Campaign
- Anaphylaxis UK
- Sinus UK
- SmellTaste
- South Asian Health Foundation
- Specialised Healthcare Alliance
- The Samter’s Society
- Professional groups
- Association for Respiratory Technology and Physiology
- Association of Respiratory Nurse Specialists
- British Association of Dermatologists
- British Paediatric Respiratory Society
- British Society for Allergy & Clinical Immunology
- British Thoracic Society
- ENT UK
- National Heart and Lung Institute
- Neonatal and Paediatric Pharmacists Group
- Primary Care Respiratory Society UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Asthma, Allergy and Inflammation Research Trust
- British Association for Lung Research
- Cochrane Airways Group
- Cochrane Ear, Nose & Throat Disorders Group
- David Hide Asthma and Allergy Research Centre
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 November 2025 | Invitation to participate |
| 27 August 2025 - 24 September 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6537 |
| 27 August 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 08 October 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 08 October 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual